Connect with us

Press Release

Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors

Published

on

Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors

Business Wire India

 − Acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging γδT cells for the potential treatment of solid tumors and hematological malignancies

− As result of successful “build-to-buy” collaboration, Takeda to exercise its right to acquire GammaDelta Therapeutics for a pre-negotiated upfront and future potential milestone payments, subject to certain adjustments

 

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. Through the acquisition, Takeda will obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005677/en/

 

“We’re committed to developing cell therapies that will have an impact on large segments of patients by focusing on off-the-shelf, allogeneic cell therapies that are highly accessible and have the potential to address solid tumors. Collaborating with scientific innovators with unique technology platforms and deep domain expertise, such as the GammaDelta team, allows Takeda to identify and accelerate the most promising approaches that can be developed into products to impact the lives of cancer patients,” said Christopher Arendt, Ph.D., Head of Oncology Cell Therapy and Therapeutic Area Unit of Takeda. “Gamma-delta T cell-based therapies represent a differentiated approach to target both solid tumors and hematological malignancies, and we are eager to integrate GammaDelta’s cell therapy platforms into our immuno-oncology R&D efforts.”

 

Takeda exercised its option to acquire GammaDelta for a pre-negotiated upfront payment as well as potential development and regulatory milestones. The acquisition follows a multi-year collaboration between Takeda and GammaDelta Therapeutics formed in 2017 to develop GammaDelta’s novel γδ T cell therapy platforms, in which Takeda received an equity stake and an exclusive right to purchase GammaDelta. The deal is expected to be finalized in Q1 of Takeda’s fiscal year 2022. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.

 

“Takeda’s exercise of their acquisition option is the culmination of years of a fruitful collaborative partnership and recognizes GammaDelta Therapeutics’ promising progress in developing novel platform technologies to treat solid tumors and hematological malignancies,” said Dr. Paolo Paoletti, CEO of GammaDelta. “Through our work together, we’ve made great strides in developing our proprietary γδ T cell therapy platforms, which have enabled the development of a pipeline of innovative cell therapies and allowed for the advancement of our first program into Phase 1 clinical development. This acquisition builds on the tremendous work of our talented team and provides the foundations to enable rapid development of a portfolio of innovative allogeneic cell therapies, focused on improving outcomes for patients with cancer.”

 

Tim Haines, Chair and Managing Partner of Abingworth, the founding investor in GammaDelta, added: “We are delighted to have been involved in the creation of GammaDelta and to have worked closely with the leadership team and alongside an excellent partner in Takeda to progress this world-class UK academic science to the next stage of its development.”

 

Takeda seeks to broaden the impact of immunotherapy in cancer treatment by focusing on mechanisms that leverage innate immunity. Innate immune responses serve as the body’s first defense mechanism against disease and involve the orchestration of a broad arsenal of mechanisms and cell types, including γδ T cells and natural killer (NK) cells, that may help to overcome cancer’s ability to evade immune recognition. GammaDelta’s cell therapy platforms include technologies designed to generate both blood- and tissue-derived allogeneic immunotherapies based on γδ T cells for the treatment of hematological malignancies and solid tumors. Both platforms have enabled the creation of a portfolio of selective non-engineered and genetically-engineered allogeneic cell therapies that are highly active preclinically against solid tumors and hematological malignancies.

 

Takeda’s Commitment to Oncology

 

Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.takedaoncology.com

 

About Takeda Pharmaceutical Company Limited

 

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https://www.takeda.com.

 

Important Notice

 

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

 

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

 

Takeda Forward-Looking Statements

 

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

About GammaDelta Therapeutics

 

GammaDelta Therapeutics (“GammaDelta”) is clinically-staged biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer. Committed to transforming the treatment of patients living with cancer, the Company is developing an ‘off-the-shelf’ therapy based on one of the body’s own immune cells, a subtype of the gamma delta (γδ) T-lymphocyte, known as the Vδ1+ T cell.

 

The Company has developed proprietary technologies to generate both blood-and tissue-derived allogeneic immunotherapies based on Vδ1 γδ T cells for the treatment of hematological malignancies and solid tumors. Both platforms have enabled the creation of non-engineered and genetically engineered allogeneic cell therapies, which demonstrate cellular activity and tumor cell killing capacity in pre-clinical models.

 

GammaDelta is advancing its novel, γδ T cell platforms and product candidates under an ongoing collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). GammaDelta’s technologies are based on pioneering world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute, and Professor Bruno Silva-Santos at the University of Lisbon. Early-stage research was facilitated in part by the support and the infrastructure of the National Institute for Health Research Guy’s and St Thomas’ Biomedical Research Centre. The formation of GammaDelta as a company was supported by Cancer Research UK Commercial Partnerships. GammaDelta’s technologies have attracted significant investment from Takeda and leading life sciences investor, Abingworth LLP.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005677/en/

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Press Release

Bitdeer Group’s Customer Obsession Approach Brings It to the World Top Player

Published

on

By

Bitdeer Group’s Customer Obsession Approach Brings It to the World Top Player

Business Wire India

Bitdeer Group, the world’s leading digital asset mining service provider, earlier announced its plans to list on the NASDAQ through a merger with the publicly traded special purpose acquisition company Blue Safari Group Acquisition Corp. The transaction values Bitdeer at an implied enterprise value of approximately $4 billion. It marks Bitdeer Group’s latest achievement on the group level and the success of its business lines that support the group’s thriving growth, which could not have been achieved without Bitdeer’s obsession with its customers that leads to the customer-centric approach throughout the years.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211126005355/en/

 

Bitdeer Group’s Customer Obsession Approach Brings It to the World Top Player (Graphic: Business Wire)

The Iceberg of Success

 

What Bitdeer Group has achieved today is only the visible part of the tip of the iceberg. Over the past years, the group has made a number of strategically decisive moves that helped sharpen its competitive edge and consolidate its leading position in this fiercely competitive market. All of this originates from and is guided by a core concept: customer obsession – the philosophy that any innovations must be driven by what truly matters to customers. For Bitdeer Group, this revolves around three key areas: 1) value-adding service offerings and user-friendly functions, 2) a stable operating entity that abides by laws and mitigates risks, and 3) data privacy and security. To better meet these needs, the group has taken an agile approach in establishing and developing its business lines.

 

Joint-effort and Achievement from Multiple Business Lines

 

As one of the business lines under Bitdeer Group and a highly trusted sharing service platform for digital assets mining, Bitdeer was first launched in December 2018. Bitdeer provided exactly what customers were desperately seeking – a simpler and more accessible approach and channel to acquire cryptocurrencies – at a time when the barrier to entry for crypto mining was a major deterring factor for individual crypto miners and enthusiasts. Alongside the evolving market trends, Bitdeer has diversified its portfolio of offerings by adding state-of-the-art cryptocurrencies and altcoins. Different service modes (Classic and Accelerator) have also been created in response to users’ varying needs. The platform is also localized in 9 languages to provide greater convenience and access to the global community.

 

Mining Datacenter, another major business line under Bitdeer Group, has recently celebrated its achievement in adopting clean and renewable energy, which is a result of its determination to grow responsibly and awareness of environmental impacts arising from the mining operation. This is a pioneering breakthrough in the industry to develop professional and standardized mining facilities, which are capable of operating at optimal levels under various climate conditions and linking up with a range of power supplies supported by the group’s proprietary innovations. It has significantly improved stability and lowered risks associated with electricity supply, so as to provide users with reliability and stability.

 

The boom of the industry on a global scale brings with it both challenges and opportunities. The Outlook of Bitdeer Group remains promising given its customer-centric approach which drives constant innovation and optimization of its products and services. No matter how Bitdeer Group evolves in the future, the mindset of ‘customer obsession’ will always come first and be at its core.

 

About Bitdeer Group

 

Bitdeer Group is the world’s leading digital asset mining service provider. It was founded by Jihan Wu, Co-Founder of Bitmain and Matrixport, with venture investment from Sequoia Capital, IDG, and other well-known investment groups in the blockchain space. Headquartered in Singapore, Bitdeer Group currently operates in the United States and Europe. The Group has three business lines — Bitdeer, Mining Datacenter, and Minerplus — demonstrating the dedication and expertise in becoming the world’s most reliable digital asset mining service provider.

 

For more information, please get in touch with Bitdeer Group:

 

Website: www.bitdeer.com
LinkedIn: www.linkedin.com/company/bitdeer-group
Sales Consultation: sales@bitdeer.com
Business Cooperation: contact@bitdeer.com
Mining Datacenter Partnership: miningcenter@bitdeer.com

 

*Information provided in this article is for general information and reference only and does not constitute nor is intended to be construed as any advertisement, professional advice, offer, solicitation, or recommendation to deal in any product. No guarantee, representation, warranty or undertaking, express or implied, is made as to the fairness, accuracy, timeliness, completeness or correctness of any information, or the future returns, performance or outcome of any product. Bitdeer expressly excludes any and all liability (to the extent permitted by applicable law) in respect of the information provided in this article, and in no event shall Bitdeer be liable to any person for any losses incurred or damages suffered as a result of any reliance on any information in this article.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211126005355/en/

Continue Reading

Press Release

Mavenir Announces Commercial Availability of 4G Open RAN-based Outdoor Small Cell

Published

on

By

Mavenir Announces Commercial Availability of 4G Open RAN-based Outdoor Small Cell

Business Wire India

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today the commercial availability of its 4G Open RAN small cell for outdoor deployments, expanding the MAVair radio and access portfolio of small cells to meet Communications Service Providers’ (CSPs) growing need for enhanced network capacity and coverage. The solution had already been tested and deployed in commercial operation with a Tier 1 European CSP.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211124006039/en/

 

Mavenir’s 4G Open RAN Small Cell for Outdoor deployments. (Photo: Business Wire)

Mavenir’s outdoor small cell (O410) is a customer driven product, that addresses a need for outdoor small cells supporting both distributed and centralized Open RAN architectures. The solution is built on Mavenir’s modular hardware architecture and highly scalable, cloud-native software platforms, the underlying principles which enabled an expedited time-to-market with full architectural and deployment flexibility. Mavenir’s expanded small cells solutions, present a future proof way of building networks that ensures interoperability, vendor competition, element security and reduced operating costs across the RAN. Mavenir’s MAVair Open RAN small cells are market-proven, carrier grade solutions, that are easy to deploy, fully automated, software upgradable, highly scalable and adaptable.

 

The outdoor small cell supports both Split 2 and S1 interfaces and can be configured remotely for full deployment flexibility and upgradability, especially effective in areas where coverage and capacity from the CSPs macro is not available, is not economically viable, or faces zoning issues, etc. Ideal deployments include rural and remote locations, sites which are constrained by size, power, backhaul, and planning restrictions. The solution is plug and play, with zero-touch provisioning and installation, powered with Power over Ethernet (PoE) and offers interfaces with the same Open RAN CU as the macro network, and with common management with macro.

 

“By leveraging our modular hardware architecture and cloud-native scalable software, Mavenir is capable of delivering new products in an agile fashion which integrate and work seamlessly with other network components deployed by CSPs. This 4G outdoor small cell is the precursor for a completely new line of 4G and 5G Open RAN-based small cell products with integrated DU, as well as Multi RAT radio access solutions in general,” said Mavenir’s Aniruddho Basu, SVP and GM of Emerging Business.

 

With the release of the 4G outdoor small cell, Mavenir now has a complete offering of Multi-G (2G/3G/4G/5G), software upgradable, Open RAN-based small cells enabling CSPs to enhance their network capacity and coverage beyond in-building use cases.

 

About Mavenir:

 

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211124006039/en/

Continue Reading

Press Release

Payhawk Raises $112 Million in the Second Largest Series B in Central and Eastern Europe

Published

on

By

Payhawk Raises $112 Million in the Second Largest Series B in Central and Eastern Europe

Business Wire India
Only seven months after closing its $20m Series A financing round, Payhawk announces its Series B of $112m all equity round led by US investor Greenoaks, who previously invested in high-growth companies like Checkout.com, Robinhood, Stripe and Brex
 
This is the second largest ever Series B for a B2B company in the CEE region after UiPath, and is the largest and fastest Series B in the spend management space across Europe
 
All existing investors, including QED Investors, Earlybird Digital East and Eleven Ventures are participating in the round
 
Payhawk currently serves companies in 27 countries with its company cards and spend management platform across Europe and will continue its global expansion with aims to open offices in the US, Netherlands, France, Australia and Singapore
 
The fintech will use the new funds to accelerate its product roadmap with the launch of a credit card in Q1 2022, and low-cost cross-border transfers as an alternative to SWIFT payments

 

Payhawk, the payments and expense solution with offices in London, Sofia, Berlin and Barcelona, has raised $112 million just three years after its inception, valuing the company at $570m. The Series B round is led by the San Francisco-based investor Greenoaks, who has a strong track record of investing in high-growth technology companies such as Gorillas, Robinhood, Stripe and Brex. All existing investors, including QED Investors, Earlybird Digital East and Eleven Ventures are participating in the round.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122006123/en/

 

Description: Hristo Borisov CEO left, Boyko Karadzhov CTO centre, Konstantin Djengozov CFO. (Photo: Business Wire)

Currently, finance teams are still bound to a high amount of manual work as they are using multiple disconnected tools for cards, payments, invoices and expense management. Payhawk reduces the amount of manual work by combining those key elements in one platform and therefore acting as a one-stop-shop for finance teams.

 

With high-growth companies, in particular, looking to digitise financial processes, Payhawk emerges as the leading platform for large SMEs and enterprise customers, especially those multinationals who have multiple offices worldwide.

 

In 2021, Payhawk introduced 3% cashback on all payments, new enterprise features, free bill payments, and support for Apple Pay and Google Pay in 30 countries. Since its Series A round, transaction volume through the platform has increased by 663% and continues to grow at 45%+ month-on-month in October. Its customer base consists of a mix of scale-ups and corporates in 27 countries across Europe, including A.T.U, Luxair, Flink, Viking Life and Wagestream.

 

In 2022, Payhawk will continue its expansion by aiming to open offices in the U.S., the Netherlands, Australia and Singapore, enabling the company to further expand its product offering by introducing credit cards and allowing smarter and cheaper cross-border transactions on top of its invoice management system.

 

These expansion and product build plans will run in tandem with growing the marketing and sales team in Payhawk’s key markets of the UK, Germany, Spain and Benelux. To further boost its enterprise focus, the company has appointed Paul Albert as SVP Global Sales, who will lead direct sales, partnerships and customer success.

 

Patrick Backhouse, a Partner of Greenoaks, said, “Ask any business owner, and they’ll tell you that managing corporate spend is among the most frustrating parts of running a company. It requires significant manual work that consumes employee time and introduces substantial room for error. Payhawk turns a fragmented process into a seamless one, providing a single place to manage the entire spending lifecycle from company cards to expenses and bill payments to invoices. We’ve been thrilled to see how fast they’ve grown, already serving a truly global customer base that’s attracted by powerful and delightful software. We think that painful expense reports and bill payments should be a thing of the past, and we are excited to partner with Payhawk on the way to getting there.”

 

Hristo Borisov, CEO and Founder at Payhawk, said, “Managing company cards, especially reports, bill payments, and invoices is currently a disconnected experience bridged by finance teams through a lot of manual work. We are building enterprise software running on global payments infrastructure that automates all spend processes. Our strong product background and engineering team allows us to move at break-neck speed. This, in turn, will enable global enterprises and fast-growing technology companies to transform how they manage their company spending, and improve efficiencies while unlocking employee time to be better spent elsewhere”

 

-ends-

 

About Payhawk
Payhawk is a financial platform that combines expense management, payments and invoice management in one solution and therefore works as a one-stop-shop for finance teams. Its customer base consists of a mix of fast-growing and mature multinational companies like LuxAir, Lotto24, Viking Life, Gtmhub, Flink, MacPaw and By Miles. Payhawk is also leading the digital transformation agenda of companies like A.T.U in Germany, where the product has replaced cash with company cards at more than 550 branches. The fintech is headquartered in London and was founded in 2018 by Hristo Borisov, Boyko Karadzhov and Konstantin Dzhengozov and is supported by renowned investors such as Greenoaks, QED Investors, Earlybird Digital East and Eleven Ventures.

 

About Greenoaks

 

Founded in 2012, Greenoaks is a global investment firm that makes concentrated, long-term investments in technology-enabled businesses around the world. At Greenoaks, we believe a small handful of companies define each generation. Our sole mission is to identify these companies early in their life cycles and partner with their founders for decades. We’ve led investments in companies such as Discord, Brex, and Rippling in the US; Deliveroo and Checkout in Europe; Coupang in South Korea; and Kavak in Latin America.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006123/en/

Continue Reading

Trending